Nature
A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice - Nature Communications
Current applications of CD40-directed cancer immunotherapy rely on the release of endogenous tumor antigen for T cell priming and activation. Here the authors develop a bispecific CD40 agonistic ...
2 days ago